Context Therapeutics Inc (CNTX)

Apr 04, 2025

Zacks.com featured highlights include Context Therapeutics, Blue Bird, Dycom Industries and Leidos - Yahoo Finance

Apr 04, 2025

Apr 03, 2025

Bet on 4 Top-Ranked Stocks With Rising P/E for Solid Gains - Yahoo Finance

Apr 03, 2025

Apr 03, 2025

Carisma Therapeutics Focuses on Strategic Alternatives Amid Revised Operating Plan - MyChesCo

Apr 03, 2025

Apr 02, 2025

Context Therapeutics Announces Participation in Key Investor Conferences - MyChesCo

Apr 02, 2025

Apr 01, 2025

Context Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Apr 01, 2025

Apr 01, 2025

Context Therapeutics Unveils Packed Schedule: 4 Elite Healthcare Conferences Coming Up - Stock Titan

Apr 01, 2025

Apr 01, 2025

Context Therapeutics: 2024 Financial and Strategic Highlights - TipRanks

Apr 01, 2025

Mar 30, 2025

Context Therapeutics to Showcase CT-95 Data at AACR 2025 - MSN

Mar 30, 2025

Mar 27, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.17 Consensus PT from Brokerages - Defense World

Mar 27, 2025

Mar 26, 2025

Context Therapeutics Announces Poster Presentation at the - GlobeNewswire

Mar 26, 2025

Mar 26, 2025

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025 - TradingView

Mar 26, 2025

Mar 26, 2025

Groundbreaking Cancer Drug Dosing Data: Context Therapeutics Reveals CT-95 Development at AACR 2025 - Stock Titan

Mar 26, 2025

Mar 24, 2025

JMP maintains $4 target on Context Therapeutics stock By Investing.com - Investing.com UK

Mar 24, 2025

Mar 24, 2025

What is HC Wainwright’s Forecast for CNTX Q3 Earnings? - Defense World

Mar 24, 2025

Mar 23, 2025

HC Wainwright Reiterates Buy Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

Mar 23, 2025

Mar 23, 2025

D. Boral Capital Reaffirms “Buy” Rating for Context Therapeutics (NASDAQ:CNTX) - Defense World

Mar 23, 2025

Mar 22, 2025

Companies Like Context Therapeutics (NASDAQ:CNTX) Are In A Position To Invest In Growth - Yahoo Finance

Mar 22, 2025

Mar 22, 2025

Context Therapeutics Reports 2024 Results and Outlines Clinical Advancements - MSN

Mar 22, 2025

Mar 21, 2025

Piper Sandler Sticks to Their Buy Rating for Context Therapeutics (CNTX) - The Globe and Mail

Mar 21, 2025

Mar 20, 2025

Context Therapeutics Inc. (CNTX) reports earnings - Quartz

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Secures 3-Year Cash Runway with $94M War Chest, Expands Cancer Pipeline - StockTitan

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Inc. Doses First Patient in Phase 1 Trial of CTIM-76 and Reports Strong Financial Position Transitioning into 2025 - Nasdaq

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Reports Full Year 2024 Operating and Financial Results - Bluefield Daily Telegraph

Mar 20, 2025

Mar 20, 2025

Context Therapeutics Inc. SEC 10-K Report - TradingView

Mar 20, 2025

Mar 17, 2025

CONTEXT THERAPEUTICS Earnings Preview: Recent $CNTX Insider Trading, Hedge Fund Activity, and More - Nasdaq

Mar 17, 2025

Mar 14, 2025

PHAXIAM THERAPEUTICS Announces the Launch of a Process to Find Buyers in the Context of its Receivership Procedure - Business Wire

Mar 14, 2025

Mar 13, 2025

Context Therapeutics (CNTX) to Release Earnings on Thursday - Defense World

Mar 13, 2025

Mar 07, 2025

Enovis Corporation Announces Participation in Upcoming Investor Conferences - MyChesCo

Mar 07, 2025

Mar 06, 2025

Integral Molecular's Out-licensed Bispecific Antibody Enters Clinical Trial for Treating Solid Tumors - StreetInsider.com

Mar 06, 2025

Mar 02, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Receives $6.33 Average PT from Analysts - Defense World

Mar 02, 2025

Feb 26, 2025

Context Therapeutics Grants Stock Options to New Employees - MSN

Feb 26, 2025

Feb 25, 2025

Context Therapeutics (NASDAQ:CNTX) Shares Up 2.1% – Time to Buy? - Defense World

Feb 25, 2025

Feb 24, 2025

Biotech Giant Context Therapeutics Lures Talent with Sweet Stock Rewards - Elblog.pl

Feb 24, 2025

Feb 24, 2025

Context Therapeutics Awards Buzzy Stock Options to New Talent, Poised for Tumor-Targeting Breakthroughs - Smartphone Magazine

Feb 24, 2025

Feb 24, 2025

Context Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 24, 2025

Feb 24, 2025

Context Therapeutics Strengthens Team with Strategic Equity Compensation Package - Stock Titan

Feb 24, 2025

Feb 21, 2025

CNTX’s Stock Journey: What Investors Need to Know About Context Therapeutics Inc’s Performance - The InvestChronicle

Feb 21, 2025

Feb 21, 2025

Why Did Warren Buffett Just Sell Investments He's Recommended Millions of Others Buy? - The Globe and Mail

Feb 21, 2025

Feb 20, 2025

Context Therapeutics to Showcase at Top 2025 Investor Conferences - MSN

Feb 20, 2025

Feb 19, 2025

There's Room to Chase These 3 Stocks Trading Near 52-Week Highs - The Globe and Mail

Feb 19, 2025

Feb 11, 2025

Centrexion stock hits 52-week low at $0.79 amid market challenges - MSN

Feb 11, 2025

Feb 08, 2025

Centrexion stock hits 52-week low at $0.9 amid market challenges - MSN

Feb 08, 2025

Feb 07, 2025

Context Therapeutics Inc (CNTX) Stock: A SWOT Analysis - The News Heater

Feb 07, 2025

Feb 05, 2025

Mineralys Therapeutics Completes Enrollment for Explore-CKD Phase 2 Trial - MyChesCo

Feb 05, 2025

Feb 05, 2025

Context Therapeutics Inc. (NASDAQ:CNTX) Given Average Rating of "Buy" by Analysts - MarketBeat

Feb 05, 2025

Feb 05, 2025

Analysts Set Context Therapeutics Inc. (NASDAQ:CNTX) PT at $6.33 - Defense World

Feb 05, 2025